Eric J Small

List of Publications by Year
in descending order

86 papers	18,082 citations	109321 35 h-index	71685 76 g-index
87 all docs	87 docs citations	87 times ranked	16652 citing authors

#	Article	IF	Citations
1	OUP accepted manuscript. Oncologist, 2022, , .	3.7	4
2	Implementation of a Multisite Financial Reimbursement Program in Cancer Clinical Trials Integrated With Patient Navigation: A Pilot Randomized Clinical Trial. JCO Oncology Practice, 2022, 18, e915-e924.	2.9	7
3	Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNÎ± Â± Bevacizumab: Results from CALGB 90206 (Alliance). Clinical Cancer Research, 2022, 28, 2771-2778.	7.0	8
4	Mobile Clinical Trial Matching Technology in Medical Oncology Clinic: A Pilot Feasibility Study. JCO Clinical Cancer Informatics, 2022, 6, e2100182.	2.1	0
5	CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease. Clinical Cancer Research, 2022, 28, 3066-3075.	7.0	10
6	Examining reporting and representation of patients with cancer in COVID â€19 clinical trials. Cancer Reports, 2021, 4, e1355.	1.4	2
7	Differential treatment outcomes in <i>BRCA1/2</i>â€, <i>CDK12</i>â€, and <i>ATM</i>â€mutated metastatic castrationâ€resistant prostate cancer. Cancer, 2021, 127, 1965-1973.	4.1	15
8	Prostateâ€specific antigen nadir and testosterone level at prostateâ€specific antigen failure following radiation and androgen suppression therapy for unfavorableâ€risk prostate cancer and the risk of allâ€cause and prostate cancerâ€"specific mortality. Cancer, 2021, 127, 2623-2630.	4.1	2
9	Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. , 2021, 9, e002254.		21
10	An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer. Nature Communications, 2021, 12, 4601.	12.8	18
11	Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance). Journal of Urology, 2021, 206, 319-324.	0.4	1
12	Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. JAMA Oncology, 2021, 7, 1644.	7.1	21
13	A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 730.e9-730.e15.	1.6	2
14	Accelerating cancer clinical trial recruitment through a financial reimbursement program integrated with patient navigation: an interrupted time series analysis. Journal of Cancer Policy, 2021, 30, 100305.	1.4	13
15	The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nature Communications, 2021, 12, 7349.	12.8	51
16	Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer. JCO Oncology Practice, 2021, , OP2100480.	2.9	1
17	Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. European Urology, 2020, 77, 333-341.	1.9	65
18	Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, e180-e189.	1.9	15

#	Article	IF	Citations
19	Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study. Prostate Cancer and Prostatic Diseases, 2020, 23, 269-276.	3.9	68
20	The DNA methylation landscape of advanced prostate cancer. Nature Genetics, 2020, 52, 778-789.	21.4	198
21	Accelerating precision medicine in metastatic prostate cancer. Nature Cancer, 2020, 1, 1041-1053.	13.2	45
22	Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. Journal of Clinical Oncology, 2020, 38, 3042-3050.	1.6	60
23	Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. JNCI Cancer Spectrum, 2020, 4, pkaa003.	2.9	1
24	Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 931.e9-931.e16.	1.6	4
25	Does the COVID-19 outbreak identify a broader need for an urgent transformation of cancer clinical trials research?. Contemporary Clinical Trials, 2020, 92, 105997.	1.8	8
26	Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors. Future Oncology, 2019, 15, 2337-2348.	2.4	15
27	The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. Clinical Cancer Research, 2019, 25, 6916-6924.	7.0	200
28	A step towards equitable clinical trial recruitment: a protocol for the development and preliminary testing of an online prostate cancer health information and clinical trial matching tool. Pilot and Feasibility Studies, 2019, 5, 123.	1.2	7
29	Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. Molecular Cancer Research, 2019, 17, 1235-1240.	3.4	51
30	Reply to A. Dalla Volta et al. Journal of Clinical Oncology, 2019, 37, 351-352.	1.6	0
31	Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. European Urology, 2019, 76, 562-571.	1.9	104
32	MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 531-538.	3.9	66
33	Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. Journal of Clinical Oncology, 2019, 37, 403-410.	1.6	83
34	How current reporting practices may mask differences: A call for examining cancer-specific demographic enrollment patterns in cancer treatment clinical trials. Contemporary Clinical Trials Communications, 2019, 16, 100476.	1.1	10
35	Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. Clinical Cancer Research, 2019, 25, 2450-2457.	7.0	52
36	Apalutamide and its use in the treatment of prostate cancer. Future Oncology, 2019, 15, 591-599.	2.4	5

#	Article	IF	Citations
37	Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 910-916.	5.0	35
38	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 479-505.	4.9	943
39	Low testosterone at first prostateâ€specific antigen failure and assessment of risk of death in men with unfavorableâ€risk prostate cancer treated on prospective clinical trials. Cancer, 2018, 124, 1383-1390.	4.1	6
40	Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy. Clinical Genitourinary Cancer, 2018, 16, 184-190.e2.	1.9	13
41	Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. Journal of Clinical Oncology, 2018, 36, 2492-2503.	1.6	477
42	Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials. Therapeutic Advances in Urology, 2018, 10, 445-454.	2.0	10
43	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell, 2018, 174, 758-769.e9.	28.9	459
44	A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naÃ¯ve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 149.e7-149.e13.	1.6	7
45	Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discovery, 2017, 7, 999-1005.	9.4	223
46	Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Molecular Cancer Research, 2017, 15, 1221-1229.	3.4	27
47	Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment. Expert Review of Anticancer Therapy, 2017, 17, 625-633.	2.4	24
48	CTâ€"Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield. Journal of Vascular and Interventional Radiology, 2017, 28, 1073-1081.e1.	0.5	30
49	Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. Journal of the National Cancer Institute, 2017, 109, .	6.3	288
50	Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. Journal of Clinical Oncology, 2017, 35, 591-597.	1.6	584
51	Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer. Oncotarget, 2017, 8, 71447-71455.	1.8	23
52	Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundationâ€"Supported West Coast Prostate Cancer Dream Team. European Urology Focus, 2016, 2, 469-471.	3.1	12
53	A Feasibility Study Showing [68Ga]Citrate PET Detects Prostate Cancer. Molecular Imaging and Biology, 2016, 18, 946-951.	2.6	33
54	Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clinical Cancer Research, 2016, 22, 4890-4900.	7.0	46

#	Article	IF	Citations
55	An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. Cancer Letters, 2016, 380, 144-152.	7.2	26
56	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of Clinical Oncology, 2016, 34, 1402-1418.	1.6	1,089
57	Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 1652-1659.	1.6	332
58	Prospects for the use of ipilimumab in treating advanced prostate cancer. Expert Opinion on Biological Therapy, 2016, 16, 421-432.	3.1	5
59	Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. Cancer Immunology Research, 2015, 3, 1008-1016.	3.4	49
60	Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. Clinical Genitourinary Cancer, 2015, 13, e191-e198.	1.9	9
61	Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. Journal of Clinical Oncology, 2015, 33, 1356-1363.	1.6	120
62	Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2015, 21, 2315-2324.	7.0	407
63	Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer. Journal of the National Cancer Institute, 2014, 106, .	6.3	163
64	Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. New England Journal of Medicine, 2013, 368, 138-148.	27.0	2,412
65	The relationship between symptomatology and treatment selection in metastatic castrate-resistant prostate cancer. Clinical Advances in Hematology and Oncology, 2011, 9, 1-15.	0.3	2
66	Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2010, 363, 411-422.	27.0	4,724
67	Immunotherapy for Prostate Cancer. American Journal of Cancer, 2006, 5, 331-339.	0.4	0
68	The Case for Secondary Hormonal Therapies in the Chemotherapy Age. Journal of Urology, 2006, 176, S66-71.	0.4	37
69	Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer. New England Journal of Medicine, 2004, 351, 1513-1520.	27.0	3,344
70	Overview of bladder cancer trials in the Cancer and Leukemia Group B. Cancer, 2003, 97, 2090-2098.	4.1	33
71	Hormonal treatment for prostate cancer. Expert Opinion on Investigational Drugs, 2001, 10, 493-510.	4.1	10
72	Serum Prostate Specific Antigen as a Predictor of Survival in Prostate Cancer Patients Treated with Second-Line Hormonal Therapy (CALGB 9181). Prostate Journal, 2001, 3, 18-25.	0.2	5

#	Article	IF	Citations
73	HER2 Protein Expression and Gene Amplification in Androgen-Independent Prostate Cancer. American Journal of Clinical Pathology, 2001, 116, 234-239.	0.7	70
74	Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma. Cancer, 2000, 88, 1310-1316.	4.1	19
75	Therapy of Advanced Prostate Cancer: Part I: Antiandrogen Withdrawal, Androgen Receptor Mutations, and Secondary Hormonal Manipulations. Prostate Journal, 2000, 2, 116-122.	0.2	0
76	Therapy of Advanced Prostate Cancer Part II: Response End Points and the Use of Chemotherapy. Prostate Journal, 2000, 2, 173-178.	0.2	0
77	Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone. Journal of Clinical Oncology, 2000, 18, 1440-1450.	1.6	176
78	Outpatient combination chemoimmunotherapy for patients with metastatic melanoma. , 1999, 86, 2160-2165.		8
79	The Treatment of Advanced Prostate Cancer with Ketoconazole. Drug Safety, 1999, 20, 451-458.	3.2	28
80	Pyrazoloacridine for the Treatment of Hormone-Refractory Prostate Cancer. Cancer Investigation, 1998, 16, 456-461.	1.3	12
81	Ketoconazole Retains Activity in Advanced Prostate Cancer Patients with Progression Despite Flutamide Withdrawal. Journal of Urology, 1997, 157, 1204-1207.	0.4	193
82	Re: Prostate Specific Antigen after Gonadal Androgen Withdrawal and Deferred Flutamide Treatment. Journal of Urology, 1996, 155, 1704-1705.	0.4	0
83	A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium. , 1996, 78, 1775-1780.		23
84	The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer, 1995, 76, 1428-1434.	4.1	162
85	Nephrectomy for metastatic renal cell carcinoma: A component of systemic treatment regimens. Journal of Surgical Oncology, 1994, 55, 7-13.	1.7	36
86	A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma. Cancer, 1994, 73, 2803-2807.	4.1	2